This Month in Business
Alimera and Allergan benefit from new FDA approvals, Allergan continues to battle Valeant, and Oculentis sues Lenstec over IOL patent infringement
- The FDA approves Alimera’s Iluvien (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME) in patients previously treated with corticosteroids who did not have a significant increase in IOP.
- Allergan’s Ozurdex (dexamethasone intravitreal implant) has had its DME indication expanded by the FDA. Formerly approved for the treatment of DME in pseudophakic adult patients or patients who were scheduled for cataract surgery, Ozurdex is now approved for the general patient population being treated for DME.
- Allergan continues to resist Valeant’s US$54 billion takeover offer. It was in talks to buy specialist pharmaceutical company, Salix, for US$11 billion, wiping out Allergan’s net cash proportion that was so attractive to Valeant, but these talks have ended for now.
- Oculentis is suing Lenstec for infringement of its UK patent for an IOL implant with an enhanced optical blending zone. It is alleged that Lenstec infringed the patent by importing and selling SBL-3 dual-topic IOLs. Oculentis is seeking an injunction against the company, as well as damages and control of the offending products.
I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.
